Rhizen receives USFDA orphan drug designation for cancer drug

The US Food and Drug Administration (USFDA) has granted orphan drug
designation for Tenalisib (RP6530) for the treatment of patients with
peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a
BSE filing.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/rhizen-receives-usfda-orphan-drug-designation-for-cancer-drug/articleshow/80401115.cms

Comments

Popular posts from this blog

Clinical Database Management Professional Vacancy @ Teva

Pharma Production Executive Post Vacancy @ Intas

Biotecnika Times – Newsletter 28.02.2020 – DST Women Scientist WOS B, DBT-IOC Recruitment